Why InfoBionic?

InfoBionic is an emerging digital health company focused on creating superior patient monitoring solutions for chronic disease management with an initial market focus on cardiac arrhythmias.

InfoBionic’s MoMe® Kardia ambulatory electrocardiograph (ECG) monitoring system is comprised of a wearable MoMe Kardia device that can acquire, store and send full disclosure ECG and other related data. This data is continuously transmitted to the cloud-based MoMe Software System using MoMe Device Communication Protocol. The proprietary software analyzes the data, which can be flagged for physician review on a Web-based physician portal.

The MoMe Kardia system supports the use of three cardiac monitoring modes—Holter monitoring, event monitoring, and mobile cardiovascular telemetry (MCT). One of MoMe Kardia’s key features is the MoMe Software System allows for a seamless transition between Holter, event or MCT monitoring, thus eliminating the need to bring the patient back to practice to change technologies.

The device has been specially designed for patients who experience transient symptoms of cardiac arrhythmias and require detection and monitoring to guide the choice of drug therapy or the success of a cardiac interventional procedure. The MoMe Kardia system perfectly suits the needs of routine cardiac monitoring as well as an adjunctive device when used in combination with other diagnostic tests.

The MoMe Kardia device has a lightweight, sleek form that makes it extremely portable and facilitates use over long periods. Being a non-invasive device, it poses no significant safety issues to patients. Its proprietary ECG acquisition and transmission technology positions the MoMe Kardia system as an ideal replacement for the complex technologies currently available.

Furthermore, the MoMe Kardia system has developed its own transformative cloud-based proprietary model that powers it to continuously stream and process data. Not only does it deliver data directly to the physician through a secure app that is Health Insurance Portability and Accountability Act (HIPAA)-compliant, it also offers analysis precision by verifying detected events through the algorithm and reduces false positives. The doctor can gain access to this monitoring data at any time of the day, anywhere in the world.

Market Opportunity

The global addressable market for monitoring cardiac arrhythmia and related events is estimated to be approximately $3 billion worldwide, including $1 billion in the U.S.

(Visited 875 times, 1 visits today)

Company Milestones

  • InfoBionic receives CE Mark for its MoMe® System for cardiac arrhythmia monitoring
  • InfoBionic appoints Steven R. Wasserman as CFO
  • InfoBionic raises $8M in Series B-1 financing led by Safeguard Scientifics
  • InfoBionic receives FDA 510(k) clearance for MoMe® Kardia
  • InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer

Making a vital change in arrhythmia detection and monitoring efficiency.